188 related articles for article (PubMed ID: 26513019)
1. UCHL1 is a biomarker of aggressive multiple myeloma required for disease progression.
Hussain S; Bedekovics T; Chesi M; Bergsagel PL; Galardy PJ
Oncotarget; 2015 Dec; 6(38):40704-18. PubMed ID: 26513019
[TBL] [Abstract][Full Text] [Related]
2. Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression.
De Smedt E; Maes K; Verhulst S; Lui H; Kassambara A; Maes A; Robert N; Heirman C; Cakana A; Hose D; Breckpot K; van Grunsven LA; De Veirman K; Menu E; Vanderkerken K; Moreaux J; De Bruyne E
Cancer Res; 2018 Mar; 78(5):1155-1168. PubMed ID: 29259009
[TBL] [Abstract][Full Text] [Related]
3. Targeting
Kamseng P; Siriboonpiputtana T; Puavilai T; Chuncharunee S; Paisooksantivatana K; Chareonsirisuthigul T; Junking M; Chiraphapphaiboon W; Yenchitsomanus PT; Rerkamnuaychoke B
Pathol Oncol Res; 2021; 27():606567. PubMed ID: 34257568
[TBL] [Abstract][Full Text] [Related]
4. MTDH is an oncogene in multiple myeloma, which is suppressed by Bortezomib treatment.
Gu C; Feng L; Peng H; Yang H; Feng Z; Yang Y
Oncotarget; 2016 Jan; 7(4):4559-69. PubMed ID: 26683226
[TBL] [Abstract][Full Text] [Related]
5. Ubiquitin C-terminal hydrolase-L1 increases cancer cell invasion by modulating hydrogen peroxide generated via NADPH oxidase 4.
Kim HJ; Magesh V; Lee JJ; Kim S; Knaus UG; Lee KJ
Oncotarget; 2015 Jun; 6(18):16287-303. PubMed ID: 25915537
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneous expression and biological function of ubiquitin carboxy-terminal hydrolase-L1 in osteosarcoma.
Zheng S; Qiao G; Min D; Zhang Z; Lin F; Yang Q; Feng T; Tang L; Sun Y; Zhao H; Li H; Yu W; Yang Y; Shen Z; Yao Y
Cancer Lett; 2015 Apr; 359(1):36-46. PubMed ID: 25578779
[TBL] [Abstract][Full Text] [Related]
7. UCH-LI acts as a novel prognostic biomarker in gastric cardiac adenocarcinoma.
Yang H; Zhang C; Fang S; Ou R; Li W; Xu Y
Int J Clin Exp Pathol; 2015; 8(11):13957-67. PubMed ID: 26823707
[TBL] [Abstract][Full Text] [Related]
8. Ubiquitin C-Terminal Hydrolase L1 is required for regulated protein degradation through the ubiquitin proteasome system in kidney.
Radón V; Czesla M; Reichelt J; Fehlert J; Hammel A; Rosendahl A; Knop JH; Wiech T; Wenzel UO; Sachs M; Reinicke AT; Stahl RAK; Meyer-Schwesinger C
Kidney Int; 2018 Jan; 93(1):110-127. PubMed ID: 28754552
[TBL] [Abstract][Full Text] [Related]
9. Over-expression of ubiquitin carboxy terminal hydrolase-L1 induces apoptosis in breast cancer cells.
Wang WJ; Li QQ; Xu JD; Cao XX; Li HX; Tang F; Chen Q; Yang JM; Xu ZD; Liu XP
Int J Oncol; 2008 Nov; 33(5):1037-45. PubMed ID: 18949367
[TBL] [Abstract][Full Text] [Related]
10. Ubiquitin C-terminal hydrolase L1 regulates the morphology of neural progenitor cells and modulates their differentiation.
Sakurai M; Ayukawa K; Setsuie R; Nishikawa K; Hara Y; Ohashi H; Nishimoto M; Abe T; Kudo Y; Sekiguchi M; Sato Y; Aoki S; Noda M; Wada K
J Cell Sci; 2006 Jan; 119(Pt 1):162-71. PubMed ID: 16371654
[TBL] [Abstract][Full Text] [Related]
11. Ubiquitin Carboxyl Terminal Hydrolase L1 Attenuates TNF-α-Mediated Vascular Smooth Muscle Cell Migration Through Suppression of NF-κB Activation.
Gao X; Wu L; Wang K; Zhou X; Duan M; Wang X; Zhang Z; Liu X
Int Heart J; 2018 Nov; 59(6):1409-1415. PubMed ID: 30305579
[TBL] [Abstract][Full Text] [Related]
12. UCH-L1 involved in regulating the degradation of EGFR and promoting malignant properties in drug-resistant breast cancer.
Jin Y; Zhang W; Xu J; Wang H; Zhang Z; Chu C; Liu X; Zou Q
Int J Clin Exp Pathol; 2015; 8(10):12500-8. PubMed ID: 26722437
[TBL] [Abstract][Full Text] [Related]
13. The S18Y polymorphic variant of UCH-L1 confers an antioxidant function to neuronal cells.
Kyratzi E; Pavlaki M; Stefanis L
Hum Mol Genet; 2008 Jul; 17(14):2160-71. PubMed ID: 18411255
[TBL] [Abstract][Full Text] [Related]
14. The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells.
Wang X; Mazurkiewicz M; Hillert EK; Olofsson MH; Pierrou S; Hillertz P; Gullbo J; Selvaraju K; Paulus A; Akhtar S; Bossler F; Khan AC; Linder S; D'Arcy P
Sci Rep; 2016 Jun; 6():26979. PubMed ID: 27264969
[TBL] [Abstract][Full Text] [Related]
15. Developmental regulation of ubiquitin C-terminal hydrolase isozyme expression during spermatogenesis in mice.
Kwon J; Wang YL; Setsuie R; Sekiguchi S; Sakurai M; Sato Y; Lee WW; Ishii Y; Kyuwa S; Noda M; Wada K; Yoshikawa Y
Biol Reprod; 2004 Aug; 71(2):515-21. PubMed ID: 15084487
[TBL] [Abstract][Full Text] [Related]
16. Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.
Chen MH; Qi C; Reece D; Chang H
Hum Pathol; 2012 Jun; 43(6):858-64. PubMed ID: 22047644
[TBL] [Abstract][Full Text] [Related]
17. The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in
Díaz T; Rodríguez V; Lozano E; Mena MP; Calderón M; Rosiñol L; Martínez A; Tovar N; Pérez-Galán P; Bladé J; Roué G; de Larrea CF
Haematologica; 2017 Oct; 102(10):1776-1784. PubMed ID: 28751557
[TBL] [Abstract][Full Text] [Related]
18. Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells.
Zaman S; Shentu S; Yang J; He J; Orlowski RZ; Stellrecht CM; Gandhi V
Neoplasia; 2015 Mar; 17(3):289-300. PubMed ID: 25810013
[TBL] [Abstract][Full Text] [Related]
19. UCH-L1 aggresome formation in response to proteasome impairment indicates a role in inclusion formation in Parkinson's disease.
Ardley HC; Scott GB; Rose SA; Tan NG; Robinson PA
J Neurochem; 2004 Jul; 90(2):379-91. PubMed ID: 15228595
[TBL] [Abstract][Full Text] [Related]
20. Control of BACE1 degradation and APP processing by ubiquitin carboxyl-terminal hydrolase L1.
Zhang M; Deng Y; Luo Y; Zhang S; Zou H; Cai F; Wada K; Song W
J Neurochem; 2012 Mar; 120(6):1129-38. PubMed ID: 22212137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
